MapLight Therapeutics
MapLight Therapeutics raises $372.5M Series D
Quick Facts
MapLight Therapeutics: Series D Funding Round
MapLight Therapeutics has successfully raised $372.5M in Series D funding.
Company Overview
Biopharma company developing medicines for brain disorders using novel drug discovery platform
Funding Details
The Series D round was led by Forbion, with participation from Goldman Sachs Alternatives.
Company Information
- Headquarters: Redwood City, CA
- Founded: 2018
- Employees: 150+
- Category: HealthTech
Investment
MapLight Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Forbion: Verified investor in Series D
- Goldman Sachs Alternatives: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
